Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.14+0.24 (+4.07%)
At close: 04:00PM EDT
5.84 -0.30 (-4.89%)
After hours: 05:24PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • c
    chott
    I am sick of all the spam on yahoo! I actually try to stay off of the MOR message board now and exclusively use (http://Themaxgains.tech)
  • M
    Martin
    $CYDY conversation
    My several thoughts about $HGEN and recently announced participation in the BET trial ("big effect trial") funded by NIAID.
    1) Lenzilumab selection was based on the compassionate use data, not on the data from the ongoing ph3 trial. This might implicate that probably no interim report data from the ongoing ph3 trial is available, which in turn might implicate that HGEN has problems with fast patients enrolment (similarly to CYDY).
    2) It is strange why now a new ph3 trial is started (with 100 patients in each arm) when another ph3 trial (with 300 patients) is already running (started already in May). The novelty regarding this new trial is that a combination of remdesivir+lenzilumab is tested as well.
    3) Actually I do not understand why this BET trial with lenzilumab (and not only with lenzilumab) has not started several months ago as soon as promising data from compassionate use has been available. At the same time (around April-May) several other arms of such trial could have been added, including leronlimab from $CYDY (targeting CCR5) or other monoclonal antibodies targeting the same cytokine (GM-CSF) as lenzilumab - i.e. mavrilimumab from $KNSA, otilimab from $MOR / $GSK, and gimsilumab from Roivant.
    4) Of course it is a good news for HGEN that NIH is interested in lenzilumab and a bad news for CYDY if leronlimab has not been considered (but this might change). But anyway, if the data from the current leronlimab trials is positive (especially in case that the S/C trial is halted by the ethical committee), there is surely no need to start a new, NIAID funded trial.
  • G
    Grifone Rampante
    Hi guys, I have a fairly trivial question, I hope someone can answer me: Morphosys is buying Constellation Pharma, currently Morphosys has 34M outstanding shares, if it bought Constellation Pharma (60M outstanding shares) Morph's outstanding shares would become 94M or it works like this only in mergers? With 34M outstanding shares Mor at these prices is highly undervalued because it has a market cap of one and a half billion, if they become 94, however, the stock could end in the 20's. Let me know, because if the shares remain 34M, I want to buy
    Bullish
  • B
    Biogemfinder1
    $EXEL conversation
    If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
    MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.
  • E
    Eugen
    MOR is going down almost every day. It will take several years to recover - if it will ever recover.Dont think that the promissing 2-3 phase data can turn this around. The bearish momentum is too strong. The shortseller have even increased their positions.Most likely we will see prices below 20#$%$ And even then it would make no sense to averange down. I should just cut my losses and move on.
    Bearish
  • C
    Chris
    Today may have been the bottom. MOR has a market cap of 1.2B yet they spent 1.7B on Constellation Pharma. This doesn't make sense to me bearing in mind their current licensed products + their own pipeline.
  • H
    Hermes
    According to chart this looks like is ready to reverse the trend. Trading Central have forecasted a very strong bullish evidence for short and medium term. It might be a good time to load...
  • S
    ScottR
    Bizarre......all the great news and a billion dollars coming in and nothing on the message boards
  • E
    Eugen
    First insider bought some shares today - Sung Lee (2000shares - CFO)
  • Z
    Zeke
    MOR basically selling for its cash-debt value.
  • H
    Hermes
    Momentum is going up and price is about to cross the 25 days MA ...
  • E
    Eugen
    This is a very strong downtrend - that started end of 2020. I am pretty sure this downtrend will continue through 2022. I would not recommend to anybody to invest here - even with this promising pipeline - and I am invested in MOR - unfortunately.

    The continuous drop in MOR has nothing to do with short positions anymore. The short rate does not change much.

    There have been also a lot of talk about MOR is a takeover candidate. I have to laugh - why should anyone buy MOR for 30euros or so. In 1-2 years MOR can be bought for less then 10 euros. But I doubt that even then someone would be interested.

    The CEO has done a terrible job - just fact - spending almost 1 billion. Not sure what he was thinking.
    The only one who is trying to work for the investors is the CFO. Buying shares - giving statements etc..

    Friendly advise - just stay away from this stock.
    Bearish
  • p
    phil
    MOR market cap is below its cash on hand
  • c
    cicio
    I am so tired of MOR doing nothing all day. Can you move??? I have been reading (http://Achieverspot.tech) for a month now and the stocks there actually go!
  • D
    Dan
    My average price is 50euros,so Im doing good........
  • L
    Luigi
    I added 200 shares again in Germany = 800 US shares. The market cap is near Cash level. Do not listen to the basers. This goes up huge just a matter of time. Approved product with royalties. More in Phase 3 for more indications. Own promising assets in Phase 3. Several other assets in the pipeline with big Pharma such as Roche Novartis Incyte...
    Bullish
  • b
    beat
    Before there will be a significant upwards trend, the results of Phase 2 trials with patients need to be successful. I expect major change only by mid 2022
  • i
    ikram
    As per zacks, it’s strong buy. Rest all is good as well. Why is it dropping everyday.
  • b
    beat
    I hope you are right. I'm not sure if the turnaround has arrived yet. Since 18 months there are only good news though a significant drop of more than 100%.
  • i
    ikram
    Pre market is good. Seems the acquisition is going to pay back
Advertisement
Advertisement